Trials / Completed
CompletedNCT01362595
Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety and possibility of giving the amino acid, leucine, in patients with Diamond Blackfan anemia(DBA)who are on dependent on red blood cell transfusions. The leucine is expected to produce a response in patients with DBA to the point where red blood cell production is increased. Red cell transfusions can then be less frequent or possibly discontinued. The investigators will study the side effects, if any, of giving leucine to DBA patients. Leucine levels of leucine will be obtained at baseline and during the study. The drug leucine will be provided in capsule form and taken 3 times a day for a total of 9 months.
Detailed description
Leucine will be provided to participants in the form of a capsule and will be taken three times daily. Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months. The entire study will last 12-15 months in length. Subjects must be two years of age or older and on transfusion for more than six months prior to enrollment.
Conditions
- Diamond Blackfan Anemia
- Blackfan Diamond Syndrome
- DBA
- Congenital Hypoplastic Anemia
- Pure Red Cell Aplasia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | leucine | Dosage of leucine will be dependent on body surface area (BSA): leucine 700 mg/m2/dose by mouth three times a day |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2018-06-30
- Completion
- 2020-11-30
- First posted
- 2011-05-30
- Last updated
- 2022-12-02
- Results posted
- 2022-12-02
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01362595. Inclusion in this directory is not an endorsement.